Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Uǧur Şahin, Petra Oehm, Evelyna Derhovanessian, et al.
Nature (2020) Vol. 585, Iss. 7823, pp. 107-112
Closed Access | Times Cited: 757

Showing 1-25 of 757 citing articles:

Lipid nanoparticles for mRNA delivery
Xucheng Hou, Tal Zaks, Róbert Langer, et al.
Nature Reviews Materials (2021) Vol. 6, Iss. 12, pp. 1078-1094
Open Access | Times Cited: 2197
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Uǧur Şahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 594-599
Open Access | Times Cited: 1837
Therapeutic cancer vaccines
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 360-378
Closed Access | Times Cited: 1082
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
Nature reviews. Cancer (2021) Vol. 21, Iss. 5, pp. 298-312
Closed Access | Times Cited: 983
Drug delivery systems for RNA therapeutics
Kalina Paunovska, David Loughrey, James E. Dahlman
Nature Reviews Genetics (2022) Vol. 23, Iss. 5, pp. 265-280
Open Access | Times Cited: 812
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Luis A. Rojas, Zachary Sethna, Kevin C. Soares, et al.
Nature (2023) Vol. 618, Iss. 7963, pp. 144-150
Open Access | Times Cited: 655
The clinical progress of mRNA vaccines and immunotherapies
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 486
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Jian Liu, Minyang Fu, Manni Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 481
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 468
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 433
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 409
Lipids and Lipid Derivatives for RNA Delivery
Yuebao Zhang, Changzhen Sun, Chang Wang, et al.
Chemical Reviews (2021) Vol. 121, Iss. 20, pp. 12181-12277
Open Access | Times Cited: 392
The dawn of mRNA vaccines: The COVID-19 case
R Verbeke, Ine Lentacker, Stefaan C. De Smedt, et al.
Journal of Controlled Release (2021) Vol. 333, pp. 511-520
Open Access | Times Cited: 391
mRNA vaccines manufacturing: Challenges and bottlenecks
Sara Sousa Rosa, D.M.F. Prazeres, Ana M. Azevedo, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2190-2200
Open Access | Times Cited: 364
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
Siri Tähtinen, Ann-Jay Tong, Patricia Himmels, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 532-542
Open Access | Times Cited: 338
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Cathrine Lund Lorentzen, John B.A.G. Haanen, Özcan Met, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 10, pp. e450-e458
Open Access | Times Cited: 327
Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
Min Qiu, Yan Tang, Jinjin Chen, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 8
Open Access | Times Cited: 315
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 310
Unlocking the promise of mRNA therapeutics
Eduarde Rohner, Ran Yang, Kylie S. Foo, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 11, pp. 1586-1600
Open Access | Times Cited: 300
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Sean A. Dilliard, Daniel J. Siegwart
Nature Reviews Materials (2023) Vol. 8, Iss. 4, pp. 282-300
Open Access | Times Cited: 295
mRNA therapeutics in cancer immunotherapy
Jan D. Beck, Daniel Reidenbach, Nadja Salomon, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 278
Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
Weiqin Jiang, Yinjun He, Wenguang He, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 257
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 245
Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery
Xu Wang, Shuai Liu, Yehui Sun, et al.
Nature Protocols (2022) Vol. 18, Iss. 1, pp. 265-291
Open Access | Times Cited: 243
Innate immune mechanisms of mRNA vaccines
R Verbeke, Michael J. Hogan, Karin Loré, et al.
Immunity (2022) Vol. 55, Iss. 11, pp. 1993-2005
Open Access | Times Cited: 230
Page 1 - Next Page

Scroll to top